Cover Image
市場調查報告書

萬古霉素抗藥性腸球菌感染疾病:開發中產品分析

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 264091
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
萬古霉素抗藥性腸球菌感染疾病:開發中產品分析 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 101 Pages
簡介

萬古黴素抗藥性腸球菌的病原性株被稱為VRE,是院內感染的主因。症狀依感染部位不同而異。細菌一般是透過腸道、傷口、尿道感染。傷口感染的情況會產生感染部位發紅、壓痛、腫起。尿道感染的情況下會有背部疼痛、排尿時產生灼熱感。其他常見的症狀還有噁心、發熱、發冷、激烈頭痛、腹瀉等。要預防感染,有效衛生管理的實行是不可或缺的。

本報告提供萬古霉素抗藥性腸球菌感染疾病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

萬古霉素抗藥性腸球菌感染疾病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

萬古霉素抗藥性腸球菌感染疾病:企業開發中的治療藥

萬古霉素抗藥性腸球菌感染疾病:大學/機關研究中的治療藥

萬古霉素抗藥性腸球菌感染疾病:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

萬古霉素抗藥性腸球菌感染疾病:企業開發中的產品

萬古霉素抗藥性腸球菌感染疾病:大學/機關研究中的產品

萬古霉素抗藥性腸球菌感染疾病的治療藥的開發企業

  • Alchemia Limited
  • Alvogen Korea Co., Ltd.
  • Aphios Corporation
  • Cellceutix Corporation
  • Helix BioMedix, Inc.
  • Hsiri Therapeutics, LLC
  • LegoChem Biosciences, Inc
  • Lytix Biopharma AS
  • MGB Biopharma Limited
  • MicuRx Pharmaceuticals, Inc.
  • Nanotherapeutics, Inc.
  • NovaBay Pharmaceuticals, Inc.
  • NovoBiotic Pharmaceuticals, LLC
  • Oragenics, Inc.
  • Sealife PHARMA GMBH
  • Sentinella Pharmaceuticals, Inc.
  • TAXIS Pharmaceuticals, Inc.
  • Wockhardt Limited

萬古霉素抗藥性腸球菌感染疾病:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

萬古霉素抗藥性腸球菌感染疾病:最近的開發平台趨勢

萬古霉素抗藥性腸球菌感染疾病:暫停中的計劃

萬古霉素抗藥性腸球菌感染疾病:開發中止的產品

萬古霉素抗藥性腸球菌感染疾病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8667IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2016, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.

Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 18 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.Vancomycin-Resistant Enterococcus faecium Infections.

Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vancomycin-Resistant Enterococcus faecium Infections Overview
  • Therapeutics Development
    • Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Overview
    • Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis
  • Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Development by Companies
  • Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Investigation by Universities/Institutes
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Vancomycin-Resistant Enterococcus faecium Infections - Products under Development by Companies
  • Vancomycin-Resistant Enterococcus faecium Infections - Products under Investigation by Universities/Institutes
  • Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development
    • Alchemia Limited
    • Alvogen Korea Co., Ltd.
    • Aphios Corporation
    • C3 Jian, Inc
    • Cellceutix Corporation
    • Helix BioMedix, Inc.
    • Hsiri Therapeutics LLC
    • LegoChem Biosciences, Inc
    • Lytix Biopharma AS
    • MGB Biopharma Limited
    • MicuRx Pharmaceuticals, Inc.
    • Nanotherapeutics, Inc.
    • NovoBiotic Pharmaceuticals, LLC
    • Oragenics, Inc.
    • Sealife PHARMA GMBH
    • Sentinella Pharmaceuticals, Inc.
    • TAXIS Pharmaceuticals, Inc.
    • Wockhardt Limited
  • Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AM-218 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BDM-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brilacidin tetrahydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chrysophaentin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • closthioamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Epimerox - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-1345 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HT-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IBN-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCB-010371 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCB-010699 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LTX-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Marinus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGBBP-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MRX-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MRX-IV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAI-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAI-108 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAI-603 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OG-253 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ramoplanin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SLP-0904 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SLP-0905 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Glycosyltransferase for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-2078 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Vancomycin Resistant Enterococci Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Teixobactin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WCK-4086 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects
  • Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products
  • Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones
    • Featured News & Press Releases
      • Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I
      • Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
      • Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140
      • May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent
      • Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H2 2016
  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alchemia Limited, H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alvogen Korea Co., Ltd., H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corporation, H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by C3 Jian, Inc, H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Cellceutix Corporation, H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Helix BioMedix, Inc., H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics LLC, H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by LegoChem Biosciences, Inc, H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Lytix Biopharma AS, H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Limited, H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Nanotherapeutics, Inc., H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics, Inc., H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sealife PHARMA GMBH, H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H2 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H2 2016
  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top